Effects of tirofiban on haemostatic activation in vitro

Kenichi A. Tanaka, N. Katori, F. Szlam, N. Sato, A. B. Kelly, A. H. Levy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban (Aggrastat®), a platelet inhibitor, as a therapy to improve heparin sensitivity and delay thrombin formation. Methods. Blood samples were obtained from healthy subjects (n=8) and cardiac surgical patients (n=34). Thrombin formation was measured in platelet-rich plasma with a Thrombogram®-Ascent fluorescent plate reader system. Platelet inhibition by tirofiban was evaluated with Plateletworks®, and the interaction of tirofiban and heparin (> 1.5 U ml-1) on clot formation was evaluated with Sonoclot Analyzer® or kaolin activated clotting times (ACTs). Results. Addition of tirofiban (70-280 ng ml-1) progressively delayed onset of thrombin generation triggered by adenosine diphosphate (ADP). Plateletworks showed platelet inhibition with tirofiban (>35 ng ml-1), whereas heparin per se failed to produce platelet inhibition at 7 U ml-1. Heparin (1.5 U ml-1) slowed the onset and rate of fibrin formation on Sonoclot analyses, and this was further slowed after addition of tirofiban (70 ng ml-1) to heparin-containing blood samples. Significant increases in ACT at all heparin concentrations were observed with the addition of tirofiban (70 ng ml-1). The addition of antithrombin (0.2 units/ml) to heparinized blood samples further prolonged ACTs, but the difference was not statistically significant when compared with heparin alone. Conclusion. Tirofiban delays platelet activation-mediated thrombin generation and prolongs ACT in heparinized blood.

Original languageEnglish
Pages (from-to)263-269
Number of pages7
JournalBritish Journal of Anaesthesia
Volume93
Issue number2
DOIs
Publication statusPublished - 2004 Aug
Externally publishedYes

Fingerprint

tirofiban
Hemostatics
Heparin
Thrombin
Blood Platelets
Hemostasis
Kaolin
In Vitro Techniques
Platelet-Rich Plasma
Antithrombins
Platelet Aggregation Inhibitors
Platelet Activation

Keywords

  • Blood, antithrombin
  • Blood, platelet inhibitors, tirofiban
  • Complications, heparin

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Tanaka, K. A., Katori, N., Szlam, F., Sato, N., Kelly, A. B., & Levy, A. H. (2004). Effects of tirofiban on haemostatic activation in vitro. British Journal of Anaesthesia, 93(2), 263-269. https://doi.org/10.1093/bja/aeh193

Effects of tirofiban on haemostatic activation in vitro. / Tanaka, Kenichi A.; Katori, N.; Szlam, F.; Sato, N.; Kelly, A. B.; Levy, A. H.

In: British Journal of Anaesthesia, Vol. 93, No. 2, 08.2004, p. 263-269.

Research output: Contribution to journalArticle

Tanaka, KA, Katori, N, Szlam, F, Sato, N, Kelly, AB & Levy, AH 2004, 'Effects of tirofiban on haemostatic activation in vitro', British Journal of Anaesthesia, vol. 93, no. 2, pp. 263-269. https://doi.org/10.1093/bja/aeh193
Tanaka KA, Katori N, Szlam F, Sato N, Kelly AB, Levy AH. Effects of tirofiban on haemostatic activation in vitro. British Journal of Anaesthesia. 2004 Aug;93(2):263-269. https://doi.org/10.1093/bja/aeh193
Tanaka, Kenichi A. ; Katori, N. ; Szlam, F. ; Sato, N. ; Kelly, A. B. ; Levy, A. H. / Effects of tirofiban on haemostatic activation in vitro. In: British Journal of Anaesthesia. 2004 ; Vol. 93, No. 2. pp. 263-269.
@article{e0bdd557757e459a92fa315b436cf519,
title = "Effects of tirofiban on haemostatic activation in vitro",
abstract = "Background. Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban (Aggrastat{\circledR}), a platelet inhibitor, as a therapy to improve heparin sensitivity and delay thrombin formation. Methods. Blood samples were obtained from healthy subjects (n=8) and cardiac surgical patients (n=34). Thrombin formation was measured in platelet-rich plasma with a Thrombogram{\circledR}-Ascent fluorescent plate reader system. Platelet inhibition by tirofiban was evaluated with Plateletworks{\circledR}, and the interaction of tirofiban and heparin (> 1.5 U ml-1) on clot formation was evaluated with Sonoclot Analyzer{\circledR} or kaolin activated clotting times (ACTs). Results. Addition of tirofiban (70-280 ng ml-1) progressively delayed onset of thrombin generation triggered by adenosine diphosphate (ADP). Plateletworks showed platelet inhibition with tirofiban (>35 ng ml-1), whereas heparin per se failed to produce platelet inhibition at 7 U ml-1. Heparin (1.5 U ml-1) slowed the onset and rate of fibrin formation on Sonoclot analyses, and this was further slowed after addition of tirofiban (70 ng ml-1) to heparin-containing blood samples. Significant increases in ACT at all heparin concentrations were observed with the addition of tirofiban (70 ng ml-1). The addition of antithrombin (0.2 units/ml) to heparinized blood samples further prolonged ACTs, but the difference was not statistically significant when compared with heparin alone. Conclusion. Tirofiban delays platelet activation-mediated thrombin generation and prolongs ACT in heparinized blood.",
keywords = "Blood, antithrombin, Blood, platelet inhibitors, tirofiban, Complications, heparin",
author = "Tanaka, {Kenichi A.} and N. Katori and F. Szlam and N. Sato and Kelly, {A. B.} and Levy, {A. H.}",
year = "2004",
month = "8",
doi = "10.1093/bja/aeh193",
language = "English",
volume = "93",
pages = "263--269",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Effects of tirofiban on haemostatic activation in vitro

AU - Tanaka, Kenichi A.

AU - Katori, N.

AU - Szlam, F.

AU - Sato, N.

AU - Kelly, A. B.

AU - Levy, A. H.

PY - 2004/8

Y1 - 2004/8

N2 - Background. Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban (Aggrastat®), a platelet inhibitor, as a therapy to improve heparin sensitivity and delay thrombin formation. Methods. Blood samples were obtained from healthy subjects (n=8) and cardiac surgical patients (n=34). Thrombin formation was measured in platelet-rich plasma with a Thrombogram®-Ascent fluorescent plate reader system. Platelet inhibition by tirofiban was evaluated with Plateletworks®, and the interaction of tirofiban and heparin (> 1.5 U ml-1) on clot formation was evaluated with Sonoclot Analyzer® or kaolin activated clotting times (ACTs). Results. Addition of tirofiban (70-280 ng ml-1) progressively delayed onset of thrombin generation triggered by adenosine diphosphate (ADP). Plateletworks showed platelet inhibition with tirofiban (>35 ng ml-1), whereas heparin per se failed to produce platelet inhibition at 7 U ml-1. Heparin (1.5 U ml-1) slowed the onset and rate of fibrin formation on Sonoclot analyses, and this was further slowed after addition of tirofiban (70 ng ml-1) to heparin-containing blood samples. Significant increases in ACT at all heparin concentrations were observed with the addition of tirofiban (70 ng ml-1). The addition of antithrombin (0.2 units/ml) to heparinized blood samples further prolonged ACTs, but the difference was not statistically significant when compared with heparin alone. Conclusion. Tirofiban delays platelet activation-mediated thrombin generation and prolongs ACT in heparinized blood.

AB - Background. Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban (Aggrastat®), a platelet inhibitor, as a therapy to improve heparin sensitivity and delay thrombin formation. Methods. Blood samples were obtained from healthy subjects (n=8) and cardiac surgical patients (n=34). Thrombin formation was measured in platelet-rich plasma with a Thrombogram®-Ascent fluorescent plate reader system. Platelet inhibition by tirofiban was evaluated with Plateletworks®, and the interaction of tirofiban and heparin (> 1.5 U ml-1) on clot formation was evaluated with Sonoclot Analyzer® or kaolin activated clotting times (ACTs). Results. Addition of tirofiban (70-280 ng ml-1) progressively delayed onset of thrombin generation triggered by adenosine diphosphate (ADP). Plateletworks showed platelet inhibition with tirofiban (>35 ng ml-1), whereas heparin per se failed to produce platelet inhibition at 7 U ml-1. Heparin (1.5 U ml-1) slowed the onset and rate of fibrin formation on Sonoclot analyses, and this was further slowed after addition of tirofiban (70 ng ml-1) to heparin-containing blood samples. Significant increases in ACT at all heparin concentrations were observed with the addition of tirofiban (70 ng ml-1). The addition of antithrombin (0.2 units/ml) to heparinized blood samples further prolonged ACTs, but the difference was not statistically significant when compared with heparin alone. Conclusion. Tirofiban delays platelet activation-mediated thrombin generation and prolongs ACT in heparinized blood.

KW - Blood, antithrombin

KW - Blood, platelet inhibitors, tirofiban

KW - Complications, heparin

UR - http://www.scopus.com/inward/record.url?scp=4344622551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344622551&partnerID=8YFLogxK

U2 - 10.1093/bja/aeh193

DO - 10.1093/bja/aeh193

M3 - Article

C2 - 15194626

AN - SCOPUS:4344622551

VL - 93

SP - 263

EP - 269

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 2

ER -